Arlesheim, Switzerland

Gerado Ramos

This inventor holds 1 USPTO granted patent. Top assignee: Sankyo Company, Limited. Active years: 1993.


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 1993

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Gerado Ramos: Innovator in Microbial Processes

Introduction

Gerado Ramos is a notable inventor based in Arlesheim, Switzerland. He has made significant contributions to the field of microbial processes, particularly in the preparation of milbemycin derivatives. His innovative work has led to advancements in the pharmaceutical industry.

Latest Patents

Gerado Ramos holds a patent for a microbial process for the preparation of milbemycin derivatives. The patent describes a one-step microbial process for creating 13.beta.-hydroxy- or 14,15-epoxy-milbemycins. This process involves bringing a milbemycin into contact with a microorganism capable of 13.beta.-hydroxylation or 14,15-epoxidation. The invention is significant for its potential applications in drug development.

Career Highlights

Gerado Ramos is associated with Sankyo Company, Limited, where he has been able to apply his expertise in microbial processes. His work has contributed to the company's research and development efforts in pharmaceuticals. With a focus on innovation, he continues to explore new methodologies in his field.

Collaborations

Gerado has collaborated with notable colleagues, including Oreste Ghisalba and Bruno Frei. These partnerships have enhanced his research and have led to fruitful outcomes in their respective projects.

Conclusion

Gerado Ramos is a distinguished inventor whose work in microbial processes has made a significant impact in the pharmaceutical industry. His patent for the preparation of milbemycin derivatives showcases his innovative approach and dedication to advancing science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…